PHARMAC is seeking feedback on a proposal to list icatibant acetate resulting from a provisional agreement formed between Shire Australia Pty Limited and PHARMAC.  

The provisional agreement is the first that PHARMAC has reached with a bidder from a Request for Proposals we ran in 2014, related to the supply of medicines for rare disorders.

In summary, this proposal would result in icatibant acetate solution for injection 30 mg/3 mL being funded in the community under Special Authority criteria and in DHB hospitals subject to restrictions. Listing in the Pharmaceutical Schedule would occur subject to Medsafe approval of the pharmaceutical.

For more details, go to: http://www.pharmac.health.nz/news/consultation-2015-07-21-icatibant/